Previous 10 | Next 10 |
2023-05-29 08:11:16 ET Summary Akebia Therapeutics Inc. is rated a Strong Buy due to its overly discounted revenue and strong prospects in the large Chronic Kidney Disease market. The company's valuation should be at least $716 million, more than 3x its current valuation, consider...
2023-05-26 15:00:30 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia Akebia Therapeutics Enters into License Agreement with Medice Arzneimit...
2023-05-23 11:27:15 ET Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight kidney disease, has seen its shares climb more than 168% so far...
2023-05-23 05:01:14 ET Akebia Therapeutics ( NASDAQ: AKBA ) regains Nasdaq compliance with the $1.00 per share minimum bid price requirement. The company is now in compliance with all applicable listing standards. On May 9, 2023, the stock was notified by Nasdaq that ...
Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass. , May 22, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives...
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis PR Newswire CAMBRIDGE, Mass. , May 22, 2023 /PRNewswire/ -- Akebia Therapeuti...
2023-05-08 10:25:25 ET Akebia Therapeutics, Inc. (AKBA) Q1 2023 Earnings Conference Call May 08, 2023, 08:30 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor and Corporate Communications John Butler - Chief Executive Officer Dave Spellma...
2023-05-08 08:17:24 ET MDJM ( MDJH ) -27% . Catalent ( CTLT ) -20% on rejecting TRC Capital's tender offer for shares BioXcel Therapeutics ( BTAI ) -15% after Q1 earning release . Baosheng Media Group Holdings ( BAOS ) -13% . Minim (...
2023-05-08 07:32:14 ET Akebia press release ( NASDAQ: AKBA ): Q1 GAAP EPS of -$0.14 beats by $0.01 . Revenue of $40.13M (-35.0% Y/Y) misses by $6.55M . For further details see: Akebia GAAP EPS of -$0.14 beats by $0.01, revenue of $40.13M misses by $6.55M
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...